EPO Ceasefire? Amgen Aranesp Price To Remain Stable Unless J&J Acts First
Executive Summary
Amgen does not intend to continue implementing Aranesp price discounts unless J&J moves first, Amgen Exec VP-Global Commercial Operations George Morrow said during an earnings call April 22
You may also be interested in...
Amgen Expects Stable Aranesp Pricing Despite J&J Lawsuit Over Rebates
Amgen anticipates pricing for its anemia therapy Aranesp (darbepoetin) to be stable regardless of the outcome of a lawsuit by Johnson & Johnson challenging its discounting practices
Amgen Expects Stable Aranesp Pricing Despite J&J Lawsuit Over Rebates
Amgen anticipates pricing for its anemia therapy Aranesp (darbepoetin) to be stable regardless of the outcome of a lawsuit by Johnson & Johnson challenging its discounting practices
Aranesp Growth Tied To Market Penetration, Not Share Gains, Amgen Says
Amgen expects future Aranesp growth to come from greater market penetration rather than market share gains as a result of the shift to average sales price-based reimbursement under Medicare Part B